1,3-Dichloropropene (1,3-D) is a soil fumigant used primarily for preplanting control of parasitic nematodes. In a previous chronic dietary exposure study, 1,3-D induced an increased incidence of hepatocellular adenomas in male rats at a dose of 25 mg/kg/day. Although the mechanism for tumor induction in the rat liver by 1,3-D has not been specifically elucidated, available data suggested that the observed liver tumorigenesis was through a nongenotoxic mode of action at the tumor promotion stage. Fischer 344 rats containing preneoplastic lesions were treated (via gavage) with 25 mg/kg/day 1,3-D or 80 mg/kg/day phenobarbital (PB) for 30 days and 60 days, or for 30 days followed by a 30-day recovery period (no compound exposure). Following treatment, placental form glutathione S-transferase (GSTP) positive and GSTP-negative liver focal lesions were quantitated as to size and number. 1,3-D treatment had no effect on GSTP-positive foci number or relative size but significantly increased the number, labeling index, and relative size of GSTP-negative focal lesions (identified by H and E staining) after 30 and 60 days of treatment. Following the 30-day recovery period, the number, labeling index, and relative size of the GSTP-negative lesions in 1,3-D-treated animals returned to control levels. As expected, PB treatment produced an increase in number and relative size of the GSTP-positive lesions. The results of this study are consistent with 1,3-D inducing liver carcinogenesis through a nongenotoxic mode of action by functioning as a tumor promoter specifically through induction of a non-GSTP staining focal hepatocyte population.
1,3-Dichloropropene (1,3-D) is a soil fumigant used in the preplanting control of parasitic nematodes. A previous cancer bioassay demonstrated significant increases in forestomach and liver tumors in Fischer 344 rats when treated with 1,3-D by gavage; however, because epichlorohydrin, a known genotoxic carcinogen, was used as a stabilizer in this study, the assessment of 1,3-D for carcinogenic potential was not possible (IARC, 1999; NTP, 1985; Stott et al., 2001 ). Subsequently, 6 additional cancer bioassays (2 inhalation studies and 4 oral exposure studies) were conducted in rodents utilizing 1,3-D without epichlorohydrin as a stabilizer (Table 1) . Of the 6 bioassays in 1, an increase in liver tumors was seen in the F344 rat following dietary exposure (Stebbins et al., 2000) . The rat liver tumors induced by 1,3-D were hepatocellular adenomas accompanied by a reported increase in the incidence of hepatic eosinophilic focal lesions in both male and female rats after 24 months of treatment (Stebbins et al., 2000) . An increase in adenomas was only statistically significant in the male rats that received the highest dose (25 mg/kg/day) of 1,3-D and the United States Environmental Protection Agency (USEPA) concluded that the neoplastic effects were treatment related (Stebbins et al., 2000) .
1,3-D undergoes conjugation with glutathione (GSH) via the glutathione S-transferase (GST) pathway and is quickly detoxified (Stott et al., 2001; Watson et al., 1987) . In a study by Bartels et al. (2004) , the 1,3-D metabolites resulting from conjugation with GSH were reported to account for 36%-55% of the administered dose excreted from male Fischer 344 rats, resulting in the depletion of GSH in the rat liver (Stott et al., 2001) . The effect that GSH depletion by 1,3-D may have an impact on the induction of liver tumors in the F344 rat by 1,3 D. Along these lines, in several in vitro studies, the addition of rodent physiological levels of GSH to the medium reduces or eliminates altogether the genotoxic response of 1,3-D (Creedy et al., 1984; Stott et al., 2001) . 1,3-D has been shown to be nongenotoxic in studies not compromised by presence of epichlorohydrin or other confounding factors (Table 2) . Thus, the presence of an active GSH detoxification pathway likely accounts for the negative findings in terms of 1,3-D genotoxicity both in vitro (in the presence of physiologic GSH and GSTs) and in vivo (Watson et al., 1987) . Based on the negative in vivo genotoxicity findings, the mechanism of 1,3-D tumorigenicity in the rat liver has been hypothesized to be through threshold-mediated non-DNA reactive events, rather than genotoxicity (Stott et al., 2001 ). The present study was undertaken to further investigate the nongenotoxic mode of action for induction of liver tumors in rats following oral (dietary) exposure to 1,3-D using a preneoplastic lesion model for rat liver carcinogenesis.
Although simplistic in definition, the carcinogen class designations of genotoxic and nongenotoxic (epigenetic) continue to provide a means of understanding the overall properties and general mechanism of action of tumorigenic agents (Klaunig et al., 2000; Klaunig, 2013; Weisburger and Williams, 1983; Williams, 1980 Williams, , 1983 . Genotoxic agents are typically described as DNA-reactive, either through binding with or damaging genomic DNA (Klaunig et al., 2000; Klaunig, 2013) . Nongenotoxic compounds do not directly induce DNA damage, but rather appear to alter early lesion growth and/or cell death resulting in exposure-related tumor formation (Klaunig et al., 2000; Klaunig, 2013 ). An important finding has been that many nongenotoxic carcinogens exert their effect at the promotion stage of carcinogenesis (Klaunig et al., 2000; Kolaja et al., 1995 Kolaja et al., , 1996 . Tumor promotion has been defined as the selective clonal expansion of preneoplastic cells and lesions as a result of either a reduction in apoptosis and/or an increase in cell proliferation, within the preneoplastic lesion (Butterworth and Goldsworthy, 1991; Klaunig, 1993; Klaunig et al., 2000; Kolaja et al., 1995; Pitot, 1990; Schulte-Hermann, 1987) . 1,3-D may be producing its tumorigenic effect by modulating the rate of growth of preexisting preneoplastic lesions in the liver of treated rats. This selective growth induction of lesion growth may account for the tumorigenicity of 1,3-D.
The effect of 1,3-D on hepatic focal lesions was examined using an established tumor-promotion model of hepatocarcinogenesis employing the growth of preneoplastic liver lesions in the Fischer 344 rat (Kolaja et al., 1995) . To aid in the evaluation of preneoplastic lesions that occurred either spontaneously or were chemically induced in the rat, the phenotypic marker, placental-form glutathione S-transferase (GSTP) has been used as a quantification and characterization tool (Sato et al., 1984; Satoh et al., 1985; Sato, 1989; Ward and Henneman, 1990) . Preneoplastic lesions immunohistochemically detected using GSTP antibodies have been shown to be the primary lesion phenotype affected by phenobarbital (PB) treatment, however other compounds, such as peroxisome proliferator-activated receptor (PPAR) alpha activators function on GSTP-negative focal lesions (Hasegawa et al., 1994) . The impact of GSTP as it relates to 1,3-D metabolism or 1,3-D carcinogenesis has not yet been delineated. Treatment protocols. At both 6 and 7 weeks of age, male F344 rats were administered 100 mg/kg diethylnitrosamine (DEN) (i.p. in sterile saline) to produce preneoplastic focal lesions in the liver (Kolaja et al., 1995; Steinmetz and Klaunig, 1996) after 16 weeks rats were randomly assigned to 1 of 3 treatment groups (control [corn oil gavage only], 1,3-D [25 mg/kg/day unstabilized in corn oil], or 80 mg/kg/day PB in saline) (n ¼ 33 rats per group, 3 groups) ( Table 3 ). The selection of the 25 mg/kg/day dose of 1,3-D was based on the previous determination of this dose as being the maximum tolerated dose from the Stebbins et al. (2000) chronic oral gavage study with F344 rats. The DEN dose and PB dose were selected based on previous studies from our laboratory (Kolaja et al., 1996) . The rats in each group were treated for either 30 days, 60 days, or 30 days followed by a 30-day recovery period (60 days total). In order to reduce the number of rats used, rats in Group 1, the control group, for the 60 day sampling and the 30 day on þ 30 day off (recovery) sampling were the same 11 rats. These 11 control rats were sampled after 60 days of corn oil gavage treatment only. Eleven (11) rats from each of the 3 treatment groups were euthanized after the treatment times. Seven days prior to sacrifice, an Alzet osmotic pump (ALZA Corporation, MountainView, California) containing 20 mg/kg of 5-bromo-2-deoxyuridine (BrdU) was surgically implanted in each of the 11 rats per group per sampling time. At the terminal sacrifice bodyweight, liver weight, kidney weight, and lung weights were determined for each animal and recorded. The liver was cut into 1-2 mm slices and along with a piece of duodenum (for quality control of BrdU incorporation) were fixed in 10% neutral buffered formalin and paraffin embedded. Cut sections were then stained with hematoxylin and eosin (H&E) or immunohistochemically with anti-BrdU or anti-GSTP (BioGenex Laboratories, Inc, San Ramon, California).
BrdU Immunohistochemistry. GSTP and BrdU immunohistochemistry was performed using the manufacturer's protocol (BioGenex Laboratories, Inc). Focal lesions were identified in H and E sections as either eosinophil or basophilic. A few clear cell lesions were found but their numbers were deemed too small to quantitate. Liver was also stained for GSTP and those lesions that stained were labeled as GSTP positive. Those focal lesions that did not stain with GSTP but were identified by H and E staining (eosinophilic or basophilic focal lesions) were designated as GSTP-negative foci. DNA synthesis in non-focal tissue was measured by counting the number of BrdU positive and negative hepatocytes in 25 fields per slide at 100Â. DNA synthesis in focal tissue was measured on slides double-stained for both BrdU and GSTP. GSTP immunohistochemistry was performed as according to the manufacturer's protocol. Focal tissue DNA synthesis was determined by counting the number of BrdU positive and negative hepatocytes in the entire lesion. The labeling index was determined as the percentage of BrdUpositive hepatocytes of the total number of hepatocytes.
Stereology. Two-dimensional morphometric analysis was made on GSTP immunohistochemically stained focal lesions and H&E stained focal lesions using a Bioquant Image Analysis program (R&M Biometrics, Inc, Nashville, Tennessee). Stereological analyses to provide liver focal lesion volume were conducted using STEREO analysis software developed at the McArdle Laboratory for Cancer Research (Madison, Wisconsin) by Xu et al. (1998) .
Representative photomicrographs of GSTP-and BrdU-stained liver sections from the treated rats are shown in Figures 1-3 . c In order to reduce the number of rats used, in Group 1, control group, the 60 day sampling and the 30 day on þ 30 day off sampling utilize the same 11 rats.
FIG. 1. Photomicrograph of a representative liver section from a 1,3-D-treated
rat stained for GSTP. Preneoplastic foci shows positive staining for GSTP (brown stain) whereas the surrounding nonlesion liver does not stain. Liver was formalin fixed, paraffin embedded, and stained with hematoxylin and anti-GSTP.
Statistical analysis. Animals were randomized prior to the start of the treatment regimen. Data from all treated groups were compared by one-way analysis of variance with Tukey's post hoc test (Gad and Weil, 1986) .
RESULTS

Effect of 1,3-D Treatment on Body and Liver Weights of DENInitiated Male Fischer 344 Rats
As noted above, using a previously reported protocol from our laboratory, male Fischer 344 rats were treated with DEN to initiate the formation of preneoplastic hepatic foci (Kolaja et al., 1995 (Kolaja et al., , 1996 Steinmetz and Klaunig, 1996) . After 16 weeks post final DENA treatment, the rats were each randomly assigned to 1 of 3 treatment groups: Group 1 (control; corn oil), Group 2 (1,3-D), or Group 3 (PB) ( Table 3) . One of 3 treatment durations for each group was performed (30 days, 60 days, or 30 days of treatment followed by a 30-day recovery period). Eleven rats per group were euthanized at each of the treatment durations.
Terminal body weights, liver weights, and relative liver weights were determined at time of sacrifice. No significant change in body weights was observed between the 3 treatment groups for each treatment duration (Table 4) . Treatment with PB (Group 3) produced an increase in liver weight and relative liver weight compared with control and 1,3-D treatment after 30 and 60 days of treatment (Table 4 ). This increase in liver weight and relative liver weight returned to control values after the 30-day recovery period (Table 4) .
Effects of 1,3-D Treatment on GSTP Positive and Negative Hepatic Foci GSTP-positive and GSTP-negative hepatic focal lesion phenotypes were identified and morphometric analyses were performed using image quantifying software. The number and volume of GSTP-positive and GSTP-negative hepatic focal lesions per liver were quantitated (Figs. 4-7) .
The number of GSTP-positive foci was significantly increased in Group 3 (PB treatment) after 30 and 60 days of treatment. After the 30 day recovery period, the number of GSTPpositive foci in PB-treated rats was reduced significantly from that seen in the 30-and 60-day-treated rats (Fig. 4) . Treatment of rats with 1,3-D for 30 days or 60 days did not increase the number GSTP-positive foci (Fig. 4) . In contrast, the number of GSTP-negative foci were significantly increased in 1,3-D-treated rats after 30 and 60 days of exposure (Fig. 5) . Following the 30-day recovery period, the number of GSTP-negative lesions in the 1,3-D group returned to control levels (Fig. 5) . PB treatment had no effect on the number of GSTP-negative focal lesions at any time point examined (Fig. 5) .
The relative GSTP-positive focal volume in rats treated with PB was increased after 30 days and 60 days (albeit only significantly from control at the 60-day sampling time). This increase in GSTP-positive focal volume returned to control levels after a 30-day recovery period (Fig. 6) . In contrast, after 30 and 60 days of treatment, 1,3-D-treated rats showed no increase in GSTPpositive focal volume and remained constant throughout the exposure and recovery period (Fig. 6) . The GSTP-negative focal volume increased in 1,3-D treated (30 days and 60 days of treatment) and PB treated (60 days of treatment) (Fig. 7) . Upon removal from treatment (the recovery group) GSTP-negative focal volume in both PB-and 1,3-D-treated rats returned to control levels (Fig. 7) .
Figures 8 and 9 show the size distribution for GSTP-positive and GSTP-negative hepatic focal lesions, respectively. An increase in the number and size of GSTP-positive foci was observed following treatment with PB for 30 days (Fig. 8A) , suggesting a promotion by PB for GSTP-positive staining foci. A further increase in the number and size of GSTP-positive foci was seen after 60 days of treatment with PB (Fig. 8B) . The PB-induced increase in foci size and number returned to control levels after a 30-day recovery period (Fig. 8C) .
In contrast to the GSTP-positive foci, an increase in GSTP-negative foci size and number was seen after 30 days treatment with 1,3-D, whereas no apparent difference in GSTP-negative foci size or number was seen following treatment with PB for 30 days (Fig. 9A) . 1,3-D produced a further increase in the size and number of GSTP-negative lesions after 60 days of treatment. Meanwhile, PB treatment also slightly increased the number and size of GSTP-negative foci at 60 days of treatment (Fig. 9B ). Similar to that seen for GSTP-positive foci, the GSTP-negative foci for both the 1,3-D and PB treatment returned to control levels after a 30-day recovery period (Fig. 9C) .
Effects of 1,3-D Treatment on DNA Synthesis in Hepatic Foci
The hepatocyte labeling index in GSTP-positive and negative focal lesions as well as in surrounding liver was determined by BrdU incorporation. No difference in the labeling index was seen in the normal surrounding hepatocytes with either of the treatments or times of exposure (Table 5 ). In GSTP-positive focal lesions, no difference in labeling index compared with untreated control focal lesions was seen with PB or 1,3-D treatment. The labeling index in the GSTP-negative focal lesions was significantly increased in the 1,3-D-treated rats (after 30 and 60 days treatment) and in the PB-treated rats (after 60 days of treatment) (Table 5 ). After the 30-day recovery period, the labeling index in the GSTP-negative focal lesions return to control levels (Table 5) .
DISCUSSION
1,3-D is a soil fumigant used primarily for preplanting control of parasitic nematodes. Chronic dietary exposure to 1,3-D was associated with increased incidence of hepatocellular adenomas in Fischer 344 rats (Lomax et al., 1989; Stebbins et al., 2000) . In contrast, in a chronic study in CD rats, 1,3-D failed to induce neoplasia ( Values represent the mean 6 SD of the body weight, liver weight, and the relative liver weight (liver-to-body weight ratio) in 11 rats per group. At both 6 and 7 weeks of age, the rats were administered 100 mg/kg DEN (i.p. in sterile saline). Sixteen weeks later, the rats were given corn oil, 25 mg/kg/day 1,3-D or 80 mg/kg/day PB for either 30 days, 60 days, or for 30 days followed by a 30-day recovery period. mutagenic (Reviewed by Stott et al., [2001] ). In fact, in a comprehensive suite of in vivo genotoxicity assays including mouse micronucleus, Big Blue mouse, 32 P post-labeling, and dominant lethal, 1,3-D was shown to be clearly negative (see Table 2 ) with positive results observed only in studies using low/unknown purity material and/or epichlorohydrin as a stabilizer (Stott et al., 2001) .
The lack of in vivo genotoxic activity, coupled with the longterm exposure data suggests that 1,3-D may be functioning through nongenotoxic mechanisms possibly by promoting the growth of spontaneously developed lesions that occur spontaneously in the rat. In a prior mechanistic investigation, examination of the effects of 1,3-D on hepatocyte growth in non-initiated (naïve) rats failed to induce an increase in cell proliferation or a decrease in apoptosis (unpublished data). and 7 weeks of age, the rats were administered 100 mg/kg DEN (i.p. in sterile saline). Sixteen weeks later, the rats were given corn oil (Group 1), 25 mg/kg/day 1,3-D (Group 2) or 80 mg/kg/day PB (Group 3) for either 30 days, 60 days, or for 30 days followed by a 30-day recovery period. The volume of lesions per liver was calculated using stereology techniques as described in Materials and Methods. Values represent the mean 6 SEM from 11 animals. Statistical significance at each time point was determined by ANOVA followed by a Tukey's post hoc test (P < 0.05).
a A statistically significant difference from 1,3-D (Group 2) at the 60-day time point.
FIG. 7.
The effects of 1,3-D or PB on the volume of GSTP-negative hepatic focal lesions per total liver volume in DEN-initiated male Fischer 344 rats. At both 6 and 7 weeks of age, the rats were administered 100 mg/kg DEN (i.p. in sterile saline). Sixteen weeks later, the rats were given corn oil (Group 1), 25 mg/kg/day 1,3-D (Group 2) or 80 mg/kg/day PB (Group 3) for either 30 days, 60 days, or for 30 days followed by a 30-day recovery period. The volume of lesions per liver was calculated using stereology techniques as described in Materials and Methods.
Values represent the mean 6 SEM from 11 animals. Statistical significance at each time point was determined by ANOVA followed by a Tukey's post hoc test Although not modifying the cell proliferation rates in normal tissue, it is possible that 1,3-D may have a selective growth stimulating effect on preneoplastic hepatic focal cells which could account for target tissue tumorigenesis in the rat liver. Therefore, the present study was undertaken to examine the potential function of 1,3-D on the tumor promotion phase of the rodent liver carcinogenesis process. In the current study, Fischer 344 rats containing DEN-induced preneoplastic focal liver lesions were treated with 25 mg/kg/day unstabilized 1,3-D (via gavage) or 80 mg/kg/day PB using protocols previously developed in our laboratory (Kolaja et al., 1995; Steinmetz and Klaunig, 1996) . Compounds that function through nongenotoxic or non-DNA-reactive mechanisms do not directly induce DNA damage but rather appear to alter cell growth and/or cell death to tip the balance in favor of overall cell division and tumor growth (Klaunig et al., 2000) . A hallmark of many nongenotoxic carcinogens has been their selective effect on focal lesion growth during the promotional stage of the multistage hepatic carcinogenesis process (Klaunig et al., 2000; Kolaja et al., 1995) . Using this rationale, the effects of 1,3-D on preneoplastic hepatic focal lesions in the rat (DEN-initiated) were investigated to provide information regarding the tumor promoting profile of this compound. PB was used as a positive control.
The identification and quantification of hepatic preneoplastic lesions in the rat can be enhanced using a immunohistochemical phenotypic marker, GSTP. The use of this marker in this study provided an immunohistochemical distinction between 2 preneoplastic phenotypes, GSTP-positive and GSTPnegative (Sato et al., 1984; Sato, 1989; Satoh et al., 1985; Ward and Henneman, 1990 ). This enzyme is an effective marker because its expression is very low in normal rat hepatocytes, but is significantly elevated in preneoplastic foci and neoplasms (Sato, 1989) . Although the substrate specificity of GSTP has not been fully characterized, it appears that GSTP may facilitate the GSH conjugation of some carcinogens (Satoh, 1998) . GSTP may be involved in the metabolism of a broad spectrum of compounds, however, any role it may play in 1,3-D detoxification, which involves GST-mediated GSH conjugation, is unknown. The relationship of the expression of GSTP in preneoplastic hepatocytes has been associated with a linkage to further neoplastic growth since both adenomas and carcinomas in the rat liver express positive GSTP staining, although a mechanistic role for GSTP in the carcinogenesis process has not be completely elucidated (Satoh and Hatayama, 2002) . A compensatory expression of GSTP as the result of a toxic insult to a cell does not necessarily explain the selective enhanced expression of this enzyme within a specific subset of preneoplastic lesions, as not all preneoplastic liver lesions are GSTP positive. It is also been reported that exposure to selective non-DNA reactive agents, specifically PPAR alpha activating compounds (peroxisome proliferators) result in a reduction in the number of GSTP-positive lesions (Hasegawa et al., 1994; Moody et al., 1991; Moore and Kitagawa, 1986; Rao et al., 1986 . The significance of this phenotypic alteration may be due to the suppressive action of peroxisome proliferators on expression and activity of GSTs as previously shown (Awasthi et al., 1984; Foliot et al., 1984 Foliot et al., , 1986 Nishimura et al., 1995) , however this has not been fully explored in vivo (Yokoyama et al., 1993) . In fact, contrary in vivo evidence shows that ciprofibrate and triiodothyronine, which cause a loss of GSTP-positive preneoplastic lesions, do not alter GSTP mRNA and protein levels (LeddaColumbano et al., 2000) . In the current study, we utilized both GSTP staining and classical H and E staining to identify and in DEN-initiated male Fischer 344 rats. At both 6 and 7 weeks of age, the rats were administered 100 mg/kg DEN (i.p. in sterile saline). Sixteen weeks later, the rats were given corn oil (Group 1), 25 mg/kg/day 1,3-D (Group 2) or 80 mg/kg/day PB (Group 3) for either 30 days (A), 60 days (B), or for 30 days followed by a 30-day recovery period (C). Foci diameters for all treatment groups were measured using the Bioquant Imaging Analysis program. Each size class represents foci diameters of 15 mm. GSTP-negative foci were measured in formalin fixed, paraffin embedded, H&E-stained liver sections. quantitate focal lesions. Those lesions that were evident by H and E staining but failed to stain with GSTP were deemed GSTP negative.
In this study, following the formation of hepatic preneoplastic lesions by DEN, subsequent treatment with PB promoted the growth of the both GSTP-positive and negative focal lesions. An increase in total GSTP-positive relative lesion volume and an increase in focal lesion number were evident with PB treatment and were in agreement with previously published research regarding PB tumor-promoting characteristics (Kolaja et al., 1995) . 1,3-D did not modulate the growth of GSTP-positive lesion size, nor did it cause an increase in the number of quantifiable GSTPpositive lesions. However, examination of GSTP-negative preneoplastic lesions (identified by H and E) indicated that 1,3-D promoted the growth of these lesions, and that this growth promotion was reversible, as demonstrated by the 30-day recovery group. Although not affecting cell proliferation rates in GSTPpositive lesions or in non-lesion tissue, 1,3-D had a significant effect on cell proliferation in GSTP-negative preneoplastic lesions. This observation indicates that 1,3-D may be causing the selective clonal expansion of GSTP-negative lesions by inducing cell proliferation within this group of altered cells. This finding suggests that 1,3-D may be functioning through a promotion of preneoplastic lesions in its induction of liver tumors following chronic treatment. The conclusion that 1,3-D is acting to promote existing foci may be supported by the lack of treatmentrelated liver tumors at the same high dose level (25 mg/kg bw/ day) in the oral gavage study in CD rats since Sprague-Dawleyderived strains typically have fewer foci compared with Fischer 344 strain rats (Kelly, 1998; Spain, 2004) .
The increase in lesion number seen with PB in the GSTPpositive foci and for 1,3-D in the GTSP-negative foci probably represents the clonal expansion of small foci to lesions large enough to be discerned histologically rather than the induction of new lesions. The significance of the selective GSTP-negative lesion promotion is unclear, however since 1,3-D treatment results in GSH depletion, and due to the requirement of GSTs for the detoxification of this compound, there may be a link to the expression of GSTP in 1,3-D promotable preneoplastic lesions. GSTs in general contribute to the phase II biotransformation of xenobiotics. It is possible that GSTP-positive lesions are less sensitive to the effects of 1,3-D promotion, due to their abundant expression of GSTP enzyme, which could be involved in its detoxification.
Reversal of the proliferative effects of 1,3-D upon removal of treatment for 30 days is consistent with 1,3-D acting on the promotion stage of the carcinogenesis process. Also consistent with a nongenotoxic promotion of tumorigenesis by 1,3-D, it was demonstrated previously using the Ha:ICR mouse skin tumor model that 1,3-D administration (approximately 4000 mg/k) followed by promotion with phorbal ester failed to demonstrate an initiation potential of 1,3-D (Van Duuren et al., 1979) . This information is underscored by the weight of evidence conclusion that 1,3-D is nongenotoxic in vivo at doses which do not lead to saturation of the GSH/GST defense system (Stott et al., 2001) (Table 2) . Overall, the profile for 1,3-D is consistent with nongenotoxic or epigenetic carcinogens such as PB (Williams and Whysner, 1996) . These data complement prior investigations in further elucidating the carcinogenic nature of 1,3-D and support the conclusion that 1,3-D is acting as a tumor promoter in tissues having a high spontaneous rate of precursor lesions.
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